UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

January 11, 2024

Study Completion Date

April 10, 2024

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

UV1

UV1 vaccine (300 μg) will be injected intradermally.

BIOLOGICAL

Sargramostim

Sargramostim (75 μg) is used as a vaccine adjuvant.

BIOLOGICAL

Ipilimumab

Ipilimumab is dosed according to label.

BIOLOGICAL

Nivolumab

Nivolumab is dosed according to label.

Trial Locations (37)

1200

Cliniques Universitaires Saint-Luc, Brussels

1714

Sykehuset Østfold HF, Grålum

2610

GZA Hospital Sint-Augustinus, Wilrijk

2650

Antwerp University Hospital, Antwerp

3000

Leuven University Hospital, Leuven

4068

Stavanger University Hospital, Stavanger

4615

Sørlandet Sykehus HF(SSHF), Kristiansand

4953

Oslo University Hospital - The Norwegian Radium Hospital, Oslo

6026

Ålesund Hospital- Helse Sunnmore HF, Ålesund

7030

St. Olavs Hospital HF, Trondheim

9019

Universitetssykehuset Nord-Norge HF, Tromsø

10029

Icahn School of Medicine at Mount Sinai, New York

13210

State University of New York (SUNY) Upstate Medical University, New York

29607

NorthShore University HealthSystem, Greenville

33308

Holy Cross Medical Group, Fort Lauderdale

34474

Ocala Oncology Center, Ocala

40241

Norton Cancer Institute, Louisville

60068

Oncology Specialists, S.C., Park Ridge

72703

Highlands Oncology Group, Fayetteville

80045

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

90404

Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica

92083

California Cancer Associates for Research & Excellence (CCARE, San Marcos

92868

University of California Irvine Health, Orange

93105

Ridley-Tree Cancer Center, Santa Barbara

85016-4880

Mayo Clinic Hospital, Phoenix

33136-1002

Sylvester Comprehensive Cancer Center, Miami

60612-3841

Rush University Medical Center - Rush University Cancer Center, Chicago

60201-1718

NorthShore University Research Institute, Evanston

68046-5706

Nebraska Cancer Specialists- Midwest Cancer Center, Papillion

14642-0001

University of Rochester, Rochester

75246-2092

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

BS2 8ED

University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Bristol

CF15 7QZ

Velindre NHS Trust, Cardiff

NW3 2QG

The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London

SM2 7LN

Royal Marsden Hospital - Institute of Cancer Research - Chelsea, London

M20 4BX

Cancer Research UK Manchester Institute, Manchester

OX3 7LE

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford

All Listed Sponsors
lead

Ultimovacs ASA

INDUSTRY

NCT04382664 - UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | Biotech Hunter | Biotech Hunter